Investigation Into Cephalon’s Actiq Winding Down
This article was originally published in The Pink Sheet Daily
Executive Summary
Connecticut Attorney General’s office will meet with Cephalon next month to discuss marketing of the pain medication.
You may also be interested in...
Cephalon Revises Fentora Labeling To Highlight Patient Selection Criteria Following Deaths
Among the deaths associated with the breakthrough cancer pain treatment were two patients prescribed the drug for migraines, Cephalon tells “The Pink Sheet” DAILY.
Cephalon Revises Fentora Labeling To Highlight Patient Selection Criteria Following Deaths
Among the deaths associated with the breakthrough cancer pain treatment were two patients prescribed the drug for migraines, Cephalon tells “The Pink Sheet” DAILY.
Lilly, AstraZeneca, Cephalon Marketing Practices Under Review By House Committee
Rep. Waxman is requesting information into the marketing of Zyprexa, Seroquel, Actiq and Fentora.